BC Innovations | Aug 15, 2019
Distillery Techniques

Targeting a KRAS allosteric site with designed ankryin repeat proteins (DARPins)

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound An AstraZeneca plc and University of Oxford team identified two DARPins that act as allosteric inhibitors of KRAS and could expand treatment of KRAS mutant cancers beyond those with...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
BC Innovations | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
BC Week In Review | Apr 27, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
BC Extra | Apr 24, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
BC Innovations | Feb 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest inhibiting RAF1 could help treat KRAS-driven lung cancer. In tumor cells from two patient-derived xenograft (PDX) mouse models of KRAS-driven lung cancer, shRNA targeting RAF1 encoded...
BC Week In Review | Jan 5, 2018
Company News

China investment company SARI acquiring majority stake in Nerviano

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($360 million), which includes an equity investment and a debt restructuring. The deal...
BC Extra | Dec 29, 2017
Company News

China's SARI acquiring Nerviano

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($356.3 million), which includes an equity investment and a debt restructuring. The deal...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Week In Review | Sep 15, 2017
Financial News

BridgeBio raises $135M round

On Sept. 13, BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital , Cormorant Capital and...
Items per page:
1 - 10 of 119